Search results
Gelclair® is a viscous gel specially formulated to aid in the painful symptoms of mucositis of the oropharyngeal cavity. It forms a protective film that, by adhering to the mucosa of the oropharyngeal cavity, can prevent further irritations thus contributing to the rapid relief of pain.
Two topical gels, Gelclair® and Zilactin®, have been shown to reduce oral mucositis by coating and protecting the mucosa before radiation treatments. Amifostine . This drug may lessen the severity of oral mucositis in people receiving radiation therapy to their head and neck when taken in advance.
Mucositis is defined as inflammatory and/or ulcerative lesions of the oral and/or gastrointestinal tract. Infectious disease, immune deficiency and medications can be causative. One of the major causes of mucositis is high-dose cancer therapy.
28 lip 2020 · The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.
Low-level laser therapy (wavelength at 650 nm, power of 40 mW, and each square cm treated with the required time to a tissue energy dose of 2 J/cm2), be used to prevent oral mucositis in patients receiving HSCT conditioned with high-dose chemotherapy, with or without total body irradiation.
The clinical effectiveness of Gelclair in the management of oral mucositis. Aust Nurs J. 2009 Apr;16 (9):30-3. PMID: 19437954.
Oral mucositis doesn’t just cause pain; it can also affect disease management and treatment outcomes. Oral mucositis can lead to: Increased risk of infection and fever 12; Prolonged hospitalisation 12; Adjustment of anti-cancer therapy 11,12; Need for artificial nutrition (i.e. a feeding tube) 11,12; Need for strong painkillers (e.g. opioids) 12
